compounded glp-1 drugs GLP-1/GIP Injections Online Compounded versions of weight loss

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

Blood Sugar Effects Both medications improve glucose metabolism: Liraglutide: HbA1c reduction of 0.5-1.0% at weight loss doses Originally developed for diabetes (Victoza) Modest glucose benefits at Saxenda doses Semaglutide: HbA1c reduction of 1.0-1.8% at diabetes doses Greater glucose improvement than liraglutide Significant benefit for prediabetes and diabetes For patients with diabetes or prediabetes, semaglutide provides greater metabolic benefit

Prescription rates for obesity medications are rising, driven by increased interest in GLP-1RA drugs

doi: 10.1093/eurheartj/ehac543

In 2022, a modified version of the GLP-1/GIP dual agonist, tirzepatide (Zepbound), developed by Eli Lilly induced an average weight loss of 21% in humans with obesity and 15% weight loss in obese patients with diabetes (1)

It is responsible for the degradation of incretins such as GLP-1